MX2018014573A - Vacuna contra el virus del zika. - Google Patents

Vacuna contra el virus del zika.

Info

Publication number
MX2018014573A
MX2018014573A MX2018014573A MX2018014573A MX2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A
Authority
MX
Mexico
Prior art keywords
nucleic acid
polypeptides
artificial nucleic
zika virus
virus vaccine
Prior art date
Application number
MX2018014573A
Other languages
English (en)
Inventor
Girerd-Chambaz Yves
Petsch Benjamin
Jasny Edith
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of MX2018014573A publication Critical patent/MX2018014573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un ácido nucleico artificial y a polipéptidos adecuados para su uso en el tratamiento o profilaxis de una infección con Virus del Zika o un trastorno relacionado con dicha infección. En particular, la presente invención se refiera a una vacuna del virus del Zika. La presente invención se dirige a un ácido nucleico artificial, polipéptidos, composiciones y vacunas que comprenden al ácido nucleico artificial o los polipéptidos. La invención además se refiere a un método para tratar o prevenir un trastorno o una enfermedad, primeros y segundos usos médicos del ácido nucleico artificial, polipéptidos, composiciones y vacunas. Además, la invención se dirige a un kit, particularmente a un kit de partes, que comprenden al ácido nucleico artificial, polipéptidos, composiciones y vacunas.
MX2018014573A 2016-02-17 2018-08-15 Vacuna contra el virus del zika. MX2018014573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016053398 2016-02-17

Publications (1)

Publication Number Publication Date
MX2018014573A true MX2018014573A (es) 2019-09-04

Family

ID=55398295

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009917A MX2018009917A (es) 2016-02-17 2017-02-17 Vacuna contra el virus del zika.
MX2018014573A MX2018014573A (es) 2016-02-17 2018-08-15 Vacuna contra el virus del zika.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009917A MX2018009917A (es) 2016-02-17 2017-02-17 Vacuna contra el virus del zika.

Country Status (6)

Country Link
US (2) US11723967B2 (es)
EP (1) EP3416683A1 (es)
BR (1) BR112018016755A2 (es)
MX (2) MX2018009917A (es)
SG (2) SG10201913630YA (es)
WO (1) WO2017140905A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
DE202015009961U1 (de) 2014-12-12 2022-01-25 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
DK3303583T3 (da) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
WO2017004143A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
CA3003055C (en) 2015-10-28 2023-08-01 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
CN109152826B (zh) * 2016-02-25 2022-11-04 宾夕法尼亚大学理事会 新抗寨卡病毒疫苗
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3452493A1 (en) 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US11478552B2 (en) 2016-06-09 2022-10-25 Curevac Ag Hybrid carriers for nucleic acid cargo
BR112018075440A2 (pt) * 2016-06-09 2019-04-02 Beth Israel Deaconess Medical Center composições e métodos para prevenir e tratar a infecção por zika vírus
EP3497246A1 (en) * 2016-08-08 2019-06-19 The Secretary of State for Health Flavivirus diagnostic assay
BR112019005183A2 (pt) 2016-09-16 2019-07-02 Pebble Labs Usa Inc sistema paratransgênico inovador para o biocontrole de mosquitos transmissores de doença
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018102659A1 (en) * 2016-12-01 2018-06-07 The Trustees Of Columbia University In The City Of New York Serological assay for zika virus infection
JP2020501545A (ja) 2016-12-08 2020-01-23 キュアバック アーゲー 肝疾患の処置または予防のためのｒｎａ
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
US11464847B2 (en) 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CN110914433A (zh) 2017-03-24 2020-03-24 库尔维科公司 编码crispr相关蛋白质的核酸及其用途
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CA3061326A1 (en) 2017-04-27 2018-11-01 The Trustees Of The University Of Pennsylvania Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019008001A1 (en) 2017-07-04 2019-01-10 Curevac Ag NEW NUCLEIC ACID MOLECULES
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US11426457B2 (en) 2017-09-21 2022-08-30 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of zika virus
JP2021501572A (ja) 2017-10-19 2021-01-21 キュアバック アーゲー 新規な人工核酸分子
WO2019090228A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
BR112020009157A2 (pt) * 2017-11-09 2020-10-27 Institut Pasteur poliepítopo quimérico, polinucleotídeo, vetor, célula hospedeira e composição imunogênica
WO2019094801A1 (en) * 2017-11-10 2019-05-16 Research Institute At Nationwide Children's Hospital Recombinant vectors encoding zika virus protein subunits
CN111601885A (zh) 2017-11-30 2020-08-28 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
SG11202004866VA (en) * 2017-12-21 2020-06-29 PEPperPRINT GmbH NS2b AS MARKER FOR ZIKA VIRUS INFECTIONS
CN108210921A (zh) * 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
AU2019205627B2 (en) * 2018-01-06 2024-05-09 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of multiple flavi virus
CN108484737B (zh) * 2018-02-09 2021-04-23 四川农业大学 坦布苏病毒非结构蛋白ns4b截短蛋白的表达方法及其产品和应用
WO2019186199A1 (en) * 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Vaccine compositions
AU2019310347A1 (en) * 2018-07-23 2021-03-04 The University Of Adelaide Zika virus vaccine
US11702453B2 (en) 2018-08-21 2023-07-18 Regents Of The University Of Michigan Materials and methods for inhibiting flavivirus infection
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
KR20220149572A (ko) * 2020-03-03 2022-11-08 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 지카 바이러스 폴리펩티드
CN111514286B (zh) * 2020-04-01 2022-03-08 中国科学院过程工程研究所 一种寨卡病毒e蛋白结合疫苗及其制备方法
EP4182297A1 (en) 2020-07-16 2023-05-24 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
CU20210063A7 (es) * 2021-07-28 2023-03-07 Ct Ingenieria Genetica Biotecnologia Antígeno recombinante para la inducción de respuesta inmune contra el virus zika
WO2023018817A1 (en) 2021-08-11 2023-02-16 Sanofi Pasteur Inc. Truncated influenza neuraminidase and methods of using the same
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2830887C (en) 2001-06-05 2016-11-29 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
KR101483715B1 (ko) 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8691961B1 (en) 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
ES2660129T3 (es) * 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
AU2013242404B2 (en) 2012-03-27 2018-08-30 CureVac SE Artificial nucleic acid molecules for improved protein or peptide expression
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
EP2854857B1 (en) 2012-05-25 2018-11-28 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
CA2915904A1 (en) 2013-08-21 2015-02-26 Curevac Ag Composition and vaccine for treating prostate cancer
WO2015024665A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Rabies vaccine
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
BR112016003358A2 (pt) 2013-08-21 2017-11-21 Curevac Ag método para aumentar a expressão de proteínas codificadas por rna
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
HUE046469T2 (hu) 2013-08-21 2020-03-30 Curevac Ag Készítmény és vakcina tüdõrák kezelésére
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PT3155129T (pt) 2014-06-10 2019-05-16 Curevac Ag Método para potenciar a produção de arn
DE202015009961U1 (de) 2014-12-12 2022-01-25 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
US20170326225A1 (en) 2014-12-16 2017-11-16 Curevac Ag Ebolavirus and marburgvirus vaccines
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
US10653768B2 (en) 2015-04-13 2020-05-19 Curevac Real Estate Gmbh Method for producing RNA compositions
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
DK3326641T3 (da) 2015-04-22 2019-09-30 Curevac Ag Rna-holdig sammensætning til behandling af tumorsygdomme
CN108064307A (zh) 2015-04-30 2018-05-22 库瑞瓦格股份公司 使用固定化的限制酶进行体外转录的方法
CN107889503A (zh) 2015-04-30 2018-04-06 库瑞瓦格股份公司 固定化的聚(n)聚合酶
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
CN107810009A (zh) 2015-05-15 2018-03-16 库瑞瓦格股份公司 涉及施用至少一种mRNA构建体的初免‑加强方案
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
EP3298142B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
DK3303583T3 (da) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
WO2016210127A1 (en) 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
ES2937963T3 (es) * 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
EP3699288A1 (en) 2015-08-07 2020-08-26 CureVac AG Process for the in vivo production of rna in a host cell
EP3334828B1 (en) 2015-08-10 2020-10-28 CureVac Real Estate GmbH Method of increasing the replication of a circular dna molecule
KR102645398B1 (ko) 2015-08-28 2024-03-07 큐어백 에스이 신규 인공 핵산 분자
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3374504A2 (en) 2015-11-09 2018-09-19 CureVac AG Optimized nucleic acid molecules
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
WO2017108087A1 (en) 2015-12-21 2017-06-29 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017137095A1 (en) 2016-02-12 2017-08-17 Curevac Ag Method for analyzing rna
EP3417069A1 (en) 2016-02-15 2018-12-26 CureVac AG Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
EP3433361A1 (en) 2016-03-24 2019-01-30 CureVac AG Immobilized inorganic pyrophosphatase (ppase)
WO2017182634A1 (en) 2016-04-22 2017-10-26 Curevac Ag Rna encoding a tumor antigen
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP3452493A1 (en) 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP3452086A1 (en) 2016-05-04 2019-03-13 CureVac AG Influenza mrna vaccines
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
US20190336611A1 (en) 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
US11478552B2 (en) 2016-06-09 2022-10-25 Curevac Ag Hybrid carriers for nucleic acid cargo
US20190381180A1 (en) 2016-06-09 2019-12-19 Curevac Ag Hybrid carriers for nucleic acid cargo
US20190185859A1 (en) 2016-08-19 2019-06-20 Curevac Ag Rna for cancer therapy
US10898566B2 (en) * 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
AU2017350488B2 (en) 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
JP2020501545A (ja) 2016-12-08 2020-01-23 キュアバック アーゲー 肝疾患の処置または予防のためのｒｎａ
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
US11464847B2 (en) 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
US11241490B2 (en) 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CN110914433A (zh) 2017-03-24 2020-03-24 库尔维科公司 编码crispr相关蛋白质的核酸及其用途
WO2019008001A1 (en) 2017-07-04 2019-01-10 Curevac Ag NEW NUCLEIC ACID MOLECULES
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
MX2020010941A (es) 2018-04-17 2021-01-29 Curevac Ag Moleculas y composiciones novedosas de arn de vsr para vacunacion.
SG11202011097YA (en) 2018-06-28 2020-12-30 Curevac Ag Bioreactor for rna in vitro transcription
BR112021009422A2 (pt) 2018-12-21 2021-10-26 Curevac Ag Rna para vacinas contra malária
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
JP2023509964A (ja) 2020-01-11 2023-03-10 シベック バイオテクノロジーズ エルエルシー 真核生物翻訳可能ｍＲＮＡの生成および真核生物への送達のための微生物システム
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines

Also Published As

Publication number Publication date
US20210205434A1 (en) 2021-07-08
US20240024453A1 (en) 2024-01-25
BR112018016755A2 (pt) 2018-12-26
MX2018009917A (es) 2019-08-14
WO2017140905A1 (en) 2017-08-24
US11723967B2 (en) 2023-08-15
SG11201806340YA (en) 2018-09-27
SG10201913630YA (en) 2020-03-30
EP3416683A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
MX2018014573A (es) Vacuna contra el virus del zika.
WO2018115507A3 (en) Henipavirus vaccine
MX2020010941A (es) Moleculas y composiciones novedosas de arn de vsr para vacunacion.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
WO2019193183A3 (en) Novel yellow fever nucleic acid molecules for vaccination
EP4233898A3 (en) Influenza mrna vaccines
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12017500450A1 (en) Flavivirus virus like particle
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX2017013879A (es) Composiciones que comprenden anakinra.